Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PE-PE: Pembrolizumab for Resectable Metastases From Kidney Cancer
NCT05578664Phase 2Active, not recruiting
- Sponsor
- Consorzio Oncotech
- Start
- Mar 2023
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in clear cell renal cell carcinoma (ccRCC), sponsored by Consorzio Oncotech. Started Mar 2023; status: active, not recruiting.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05578664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578664.